Monika Brueggemann | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Monika Brueggemann is active.

Explore More

Publication

Featured researches published by Monika Brueggemann.

Blood | 2010

Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003

Dieter Hoelzer; Andreas Huettmann; Felix Kaul; Sebastian Irmer; Nadja Jaekel; Martin Mohren; Thomas Lipp; Knut Wedelin; Francisco de Valle; Mathias Schmid; Eckhard Thiel; Monika Brueggemann; Michael Kneba; Nicola Goekbuget

Blood | 2012

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Max S. Topp; Nicola Goekbuget; Gerhard Zugmaier; Andreas Viardot; Matthias Stelljes; Svenja Neumann; Heinz A. Horst; Albrecht Reichle; Reinhard Marks; Christoph Faul; Monika Brueggemann; Matthias Ritgen; Petra Klappers; Noemi Mergen; Marie-Elisabeth Goebeler; Hermann Einsele; Ralf C. Bargou

Blood | 2012

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget; Joachim Beck; Monika Brueggemann; Thomas Burmeister; Eike C. Buss; Norbert Frickhofen; Andreas Huettmann; Anke Morgner; Albrecht Reichle; Ingo G.H. Schmidt-Wolf; Stefan Schwartz; Hubert Serve; Bernd M. Spriewald; Michael Starck; Matthias Stelljes; Andreas Viardot; Knut Wendelin; Dieter Hoelzer

Blood | 2010

PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003

Nicola Goekbuget; Anja Baumann; Joachim Beck; Monika Brueggemann; Helmut Diedrich; Andreas Huettmann; Lothar Leimer; Stefan Zewen; Martin Mohren; Albrecht Reichle; Markus Schaich; Kerstin Schaefer-Eckart; Marc Schmalzing; Mathias Schmid; Hubert Serve; Reingard Stuhlmann; Theis Terwey; Dieter Hoelzer

Blood | 2008

PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

Nicola Goekbuget; Anja Baumann; Joachim Beck; Joachim Boos; Monika Brueggemann; Helmut Diedrich; Andreas Hüttmann; Lothar Leimer; Thomas Lipp; Ralph Naumann; Martin Mohren; Albrecht Reichle; Kerstin Schäfer-Eckart; Marc Schmalzing; Mathias Schmid; Norbert Schmitz; Theis Therwey; Dieter Hoelzer

Blood | 2009

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Nicola Goekbuget; Monika Brueggemann; Renate Arnold; Claus-Rainer Bartram; Rainer Fietkau; Mathias Freund; Arnold Ganser; Michael Kneba; Thomas Lipp; Wolf-Dieter Ludwig; Georg Maschmeyer; Dorle Messerer; Thorsten Raff; Harald Rieder; Eckhard Thiel; Dieter Hoelzer

Blood | 2013

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Alexander Kohlmann; Giovanni Martinelli; Wolf-Karsten Hofmann; Geertruy te Kronnie; Sabina Chiaretti; Claude Preudhomme; Enrico Tagliafico; Jesús Hernández; Christian Gabriel; Thomas Lion; Peter Vandenberghe; Katerina Machova Polakova; Marie-Christine Béné; Monika Brueggemann; Giovanni Cazzaniga; Allen Eng Juh Yeoh; Sören Lehmann; Thomas Ernst; Elisabeth Oppliger Leibundgut; Ugur Ozbek; Ken I. Mills; Martin Dugas; Christian Thiede; Orietta Spinelli; Letizia Foroni; Joop H. Jansen; Andreas Hochhaus; Torsten Haferlach

Blood | 2014

Long-Term Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Achieved Minimal Residual Disease (MRD) Response Following Anti-CD19 BiTE ® Blinatumomab

Gerhard Zugmaier; Nicola Goekbuget; Andreas Viardot; Matthias Stelljes; Svenja Neumann; Heinz A. Horst; Albrecht Reichle; Reinhard Marks; Christoph Faul; Monika Brueggemann; Chris Holland; Margit Schmidt; Noemi Mergen; Marie-Elisabeth Goebeler; Hermann Einsele; Ralf C. Bargou; Max S. Topp

Blood | 2010

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp; Gerhard Zugmaier; Nicola Goekbuget; Svenja Neumann; Heinz-August Horst; Thorsten Raff; Monika Brueggemann; Michael Kneba; Andreas Viardot; Mathias Schmid; Markus Schaich; Matthias Stelljes; Mariele Goebeler; Heike Pfeiffer; Oliver G. Ottmann; Thomas Burmeister; Evelyn Degenhard; Margit Schmidt; Jürgen Scheele; Hermann Einsele; Peter Kufer; Matthias Klinger; Dirk Nagorsen; Dieter Hoelzer; Ralf C. Bargou

Journal of Clinical Oncology | 2018

Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT).

Max S. Topp; Anthony S. Stein; Gerhard Zugmaier; Hervé Dombret; Monika Brueggemann; Massimiliano Bonifacio; Xiaoyu Dong; Hagop M. Kantarjian; Ralf C. Bargou; Nicola Gökbuget

Explore More